Tyrosine Kinase Inhibitors: all 10,479 studies that test it
Page 77 of 105. Open to participants first (1,915), then studies with results posted, then the rest; newest registration first within each.
- Paediatric Hepatic International Tumour TrialActive, not recruitingNCT03017326Phase 3
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantTerminatedNCT03015792Phase 1
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid TumorCompletedNCT03009292Phase 1
- Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLCStatus unknownNCT03008109Phase 3
- The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric CancerStatus unknownNCT03007446Phase 2
- A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT03006068Phase 3
- Lenvatinib in Second Line Endometrial CarcinomaWithdrawnNCT03005015Phase 2
- Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCompletedNCT03004768Phase 1
- EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT03002844Phase 2
- Study of Tofacitinib in Refractory DermatomyositisCompletedNCT03002649Phase 1
- Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLCCompletedNCT03001609Phase 1
- Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate CancerCompletedNCT02998242Not applicable
- Ruxolitinib for Steroid-refractory GVHDCompletedNCT02997280Phase 2
- Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)Status unknownNCT02995187Phase 2
- Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTCTerminatedNCT02992340Phase 1/2
- Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCTerminatedNCT02991651Phase 1
- Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus CarriersStatus unknownNCT02991638Phase 3
- Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular CarcinomaWithdrawnNCT02989870Phase 1
- Apatinib for Advanced Non-squamous Head and Neck CancerStatus unknownNCT02989259Phase 2
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
- Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaStatus unknownNCT02981745Phase 1/2
- Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung CancerStatus unknownNCT02980809Phase 2
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedNCT02979821Phase 2
- Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade GliomasCompletedNCT02978261Phase 1
- A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid TumoursStatus unknownNCT02977364Phase 1
- Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard TreatmentCompletedNCT02976896Phase 2
- A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung CancerCompletedNCT02976116Phase 2
- Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic CancerStatus unknownNCT02975141Phase 1
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung CancerTerminatedNCT02973763Phase 1
- A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerStatus unknownNCT02973737Phase 3
- A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CMLWithdrawnNCT02973711Phase 1/2
- Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLLTerminatedNCT02973399Phase 1
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCLActive, not recruitingNCT02972840Phase 3
- Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790MStatus unknownNCT02972333Phase 3
- Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.CompletedNCT02971696Phase 3
- Safety and Tolerability Study of K0706 in Subjects With Parkinson's DiseaseCompletedNCT02970019Phase 1
- Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaCompletedNCT02966821Phase 2
- Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial ChemoimmunotherapyTerminatedNCT02966730Early Phase 1
- A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid MalignanciesTerminatedNCT02966171Phase 1
- A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaCompletedNCT02966093Phase 3
- The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second LineTerminatedNCT02962388Phase 2/3
- Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR MutationStatus unknownNCT02961270Phase 2
- Open-Label Crossover Study Comparing CTP-543 to Jakafi®CompletedNCT02960945Phase 1
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLCStatus unknownNCT02960607Phase 2
- Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung CancerCompletedNCT02959749Phase 2/3
- Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALKCompletedNCT02959619Phase 1
- An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
- RICE-ibrutinib in Relapsed DLBCLStatus unknownNCT02955628Phase 2
- Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT02953743Phase 1
- Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of ImprovementTerminatedNCT02952573Phase 2
- Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled TrialStatus unknownNCT02951637Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2
- A+C in Metastatic Lung Adenocarcinoma CancerStatus unknownNCT02946359Phase 2
- Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.CompletedNCT02945852Phase 2
- Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian CancerTerminatedNCT02943317Phase 1
- The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck CancerStatus unknownNCT02943252Phase 2
- Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic CarcinomaStatus unknownNCT02942693Phase 2
- Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric CancerStatus unknownNCT02942329Phase 1/2
- Study of Ixazomib and Erlotinib in Solid TumorsCompletedNCT02942095Phase 1
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2
- Capecitabine and Lenvatinib With External Radiation in Rectal AdenocarcinomaCompletedNCT02935309Phase 1
- Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related TumorsCompletedNCT02934256Phase 2
- Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingNCT02932280Phase 1/2
- Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLCStatus unknownNCT02929290Phase 1
- Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With GlioblastomaStatus unknownNCT02928575Phase 2
- A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial LesionsStatus unknownNCT02927340Phase 2
- Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid TumorsCompletedNCT02926768Phase 1
- Regorafenib in Relapsed GlioblastomaCompletedNCT02926222Phase 2
- A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.CompletedNCT02925104Phase 1
- Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney ImpairmentCompletedNCT02923947Phase 1
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.CompletedNCT02922777Phase 1
- Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)Status unknownNCT02919371Phase 1/2
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
- 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patientsActive, not recruitingNCT02917720Phase 2
- Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With MyelofibrosisCompletedNCT02917096Phase 1
- Kanitinib in Treating Patients With Advanced Solid TumorsCompletedNCT02916095Phase 1
- Lenvatinib and Capecitabine in Patients With Advanced MalignanciesWithdrawnNCT02915172Phase 1
- Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsCompletedNCT02914990Phase 1
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
- Safety and Activity of SNX-5422 Plus Ibrutinib in CLLWithdrawnNCT02914327Phase 1
- A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male SubjectsCompletedNCT02913716Phase 1
- Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia PatientsStatus unknownNCT02912754Phase 1/2
- Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
- Relieving Chronic Itch: Oral MedicationWithdrawnNCT02909569Phase 2
- Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
- Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal CancerCompletedNCT02906059Phase 1
- Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell LymphomasCompletedNCT02900716Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung CancerStatus unknownNCT02897479Phase 2
- First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001CompletedNCT02896231Phase 1
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy SubjectsStatus unknownNCT02892370Phase 1
- Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell LymphomasCompletedNCT02891590Phase 1
- Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
- Dasatinib Holiday for Improved TolerabilityCompletedNCT02890784Phase 3